The company said the 'password era is ending'.
Taipei-based biotech company Jyong Biotech Ltd. has leveraged a successful IPO to accelerate the development of MCS-2, a promising treatment for benign prostatic hyperplasia (BPH).
‘People don't want their homes to be reviewed by anyone from burglars through to stalkers.’
They only appeared in public three days ago and already have over half a million listens.